DHEA-S Sex- and Cycle-Related Differences: Normal Ranges, Optimal Levels, and What They Mean

By
Published Updated Last reviewed
Medical lab testing image for DHEA-S Sex- and Cycle-Related Differences: Normal Ranges, Optimal Levels, and What They Mean

At a glance

  • Peak age / mid-20s in both sexes
  • Decline rate / approximately 2 to 3% per year after age 30
  • Adult male range / 280 to 640 mcg/dL (typical laboratory reference)
  • Adult female range / 65 to 380 mcg/dL (varies by lab and cycle phase)
  • Postmenopausal female range / 15 to 170 mcg/dL
  • Half-life / 7 to 10 hours (much longer than unconjugated DHEA at 15 to 30 minutes)
  • Primary source / adrenal cortex (roughly 90%); ovaries and testes contribute ~10%
  • Cycle variation / luteal-phase values run 5 to 15% lower than early follicular
  • Longevity signal / DHEA-S below 100 mcg/dL in adults under 60 associated with increased cardiovascular risk in multiple cohort studies
  • Actionable threshold / most longevity-oriented clinicians target 150 to 350 mcg/dL regardless of sex

What DHEA-S Is and Why the Sulfate Form Matters

DHEA-S is the sulfated, water-soluble storage form of DHEA. Because it is not bound to sex-hormone-binding globulin (SHBG) and has a half-life of 7 to 10 hours rather than the 15 to 30 minutes of free DHEA, it provides a far more stable snapshot of adrenal androgen output [1]. A single morning blood draw is sufficient. Intraday variability is low enough that repeat testing within the same week rarely changes clinical interpretation.

How DHEA-S Differs from DHEA

DHEA and DHEA-S interconvert freely via sulfotransferase (SULT2A1) and steroid sulfatase enzymes in the liver, gut, and adrenal gland [2]. The ratio of DHEA-S to free DHEA in serum is roughly 300:1, which is why DHEA-S dominates the clinical measurement. Peripheral tissues, including breast, prostate, skin, and bone, cleave the sulfate group locally to generate biologically active androgens and estrogens without raising systemic sex-steroid levels. This intracrine pathway is clinically important: it means DHEA-S exerts tissue-level effects that a standard hormone panel may not capture.

Why Assay Method Matters

Reference ranges differ by assay platform. Immunoassay-based DHEA-S measurements (used by most commercial labs) run 10 to 20% higher than liquid chromatography-tandem mass spectrometry (LC-MS/MS) values [3]. When comparing your result to a published reference range, confirm that the lab used the same method. The HealthRX lab panel uses LC-MS/MS for all adrenal steroids.

Reference Ranges by Sex

DHEA-S concentrations in men run consistently higher than in women across every adult age band. The difference is not trivial. A 35-year-old man at the 50th percentile will typically measure around 350 to 400 mcg/dL; a 35-year-old woman at the same percentile measures around 180 to 220 mcg/dL [4].

Men

In a large cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES), median DHEA-S in men aged 20 to 29 was approximately 429 mcg/dL, falling to 258 mcg/dL in men aged 40 to 49 and 179 mcg/dL in men aged 60 to 69 [5]. The Endocrine Society does not publish a single male-specific optimal target, but a 2021 review in the Journal of Clinical Endocrinology and Metabolism described values below 80 mcg/dL in men under 60 as "frankly deficient" and warranting adrenal evaluation [6].

Typical adult male reference intervals by decade:

| Age (years) | Reference range (mcg/dL) | |-------------|--------------------------| | 18 to 29 | 280 to 640 | | 30 to 39 | 220 to 550 | | 40 to 49 | 160 to 450 | | 50 to 59 | 110 to 370 | | 60 to 69 | 70 to 290 | | 70+ | 40 to 200 |

Women

Women's ranges are lower and narrower [4]. The adrenal gland produces proportionally less DHEA-S in women, and peripheral conversion of adrenal precursors accounts for a larger fraction of total androgen exposure. Ovarian stromal cells also contribute roughly 10 to 15% of circulating DHEA-S in premenopausal women, which partially explains cycle-phase variation (see the next section).

Typical adult female reference intervals by decade:

| Age (years) | Reference range (mcg/dL) | |-------------|--------------------------| | 18 to 29 | 145 to 395 | | 30 to 39 | 100 to 340 | | 40 to 49 | 65 to 280 | | 50 to 59 | 40 to 200 | | Postmenopause | 15 to 170 |

Menstrual Cycle Variation in DHEA-S

DHEA-S does not show the sharp mid-cycle spike that LH and estradiol exhibit, but it is not cycle-invariant either. Studies using daily blood sampling show a consistent pattern: values are highest in the early follicular phase (days 1 to 5), fall modestly around ovulation, and reach their nadir in the mid-to-late luteal phase [7].

Magnitude of Cycle-Phase Changes

A 1998 longitudinal study by Casson et al. Measuring DHEA-S daily across 28-day cycles in 12 healthy women found peak-to-trough variation of approximately 15 to 18% within the same individual [7]. That magnitude is small relative to estradiol (which varies 10-fold) but large enough to affect interpretation near reference-range boundaries. A woman at 145 mcg/dL on day 3 of her cycle might test at 124 mcg/dL on day 22, crossing the lower boundary of her lab's reference range without any true change in adrenal function.

Practical Testing Advice for Women

For the most reproducible result, women who are still cycling should draw DHEA-S on days 3 to 7 of the menstrual cycle, concurrent with their baseline FSH and estradiol. This convention is used in fertility workups and adrenal assessments alike [8]. Postmenopausal women and women on hormonal contraception can test on any day.

Hormonal Contraception and DHEA-S

Combined oral contraceptives (COCs) suppress DHEA-S by 25 to 50% through two mechanisms: suppression of LH (reducing the small ovarian contribution) and an estrogen-driven increase in SHBG and cortisol-binding globulin that indirectly down-regulates adrenal androgen synthesis [9]. A woman who stopped a COC within the past 3 to 6 months may have artificially low DHEA-S. The ACOG recommends noting contraceptive status on all androgen-panel requisitions [10].

Age-Related Decline (Adrenopause)

The fall of DHEA-S with aging is one of the most consistent endocrine findings in the literature. The phenomenon is called adrenopause. Unlike menopause, it has no clinical threshold and no consensus treatment protocol, but its prognostic implications are substantial.

Rate of Decline

DHEA-S falls at roughly 2 to 3% per year after age 30 in both sexes [11]. By age 70, most individuals have DHEA-S concentrations 80 to 90% below their personal peak. The Baltimore Longitudinal Study of Aging followed 892 men and women over two decades and confirmed this linear decline independent of BMI, smoking status, or comorbidity [11].

Cardiovascular and Mortality Associations

Low DHEA-S predicts adverse outcomes in multiple prospective cohorts. The Rancho Bernardo Study (N = 1,084 community-dwelling adults followed for up to 19 years) found that men in the lowest DHEA-S quartile had a relative risk of cardiovascular mortality of 1.67 (95% CI 1.09 to 2.54) compared with the highest quartile [12]. A 2020 meta-analysis of 22 prospective studies (combined N = 38,427) published in Ageing Research Reviews found that each 100 mcg/dL lower DHEA-S was associated with a 10% higher all-cause mortality risk (HR 1.10, 95% CI 1.06 to 1.14) [13].

These associations are not proof of causation. DHEA-S may be a marker of overall adrenal reserve rather than a direct mediator of cardiovascular protection. Randomized trials of DHEA supplementation have not consistently replicated the benefit seen in observational data.

Adrenal Reserve and DHEA-S in Aging

The HealthRX Adrenal Reserve Interpretation Framework classifies DHEA-S results in the context of age-adjusted percentile rather than absolute value alone:

  • Percentile 70 to 100 for age/sex: Likely adequate adrenal reserve. No intervention indicated.
  • Percentile 30 to 69 for age/sex: Borderline. Assess cortisol awakening response, morning cortisol, and symptom burden (fatigue, low libido, poor recovery).
  • Percentile <30 for age/sex: Consistent with reduced adrenal reserve. Consider formal adrenal workup and discussion of DHEA supplementation if symptomatic.

This framework is used in HealthRX clinical reviews and aligns with the approach described by Baulieu et al. In the DHEA-AGE trial and the functional medicine adrenal assessment literature.

What "Optimal" DHEA-S Means

"Normal range" and "optimal range" are not the same thing. A laboratory reference interval is derived from the middle 95% of a reference population, which includes sedentary, metabolically unhealthy, and aging individuals [14].

Longevity-Oriented Targets

Longevity-focused clinicians generally target DHEA-S in the upper quartile of the 30-year-old reference range for the patient's sex. In practice, that translates to:

  • Men: 350 to 500 mcg/dL
  • Women: 200 to 350 mcg/dL

These targets are not endorsed by a single society guideline but are derived from the observational data showing lowest all-cause mortality in the highest DHEA-S tertile [13]. The Endocrine Society's 2015 statement on androgen therapy states that "DHEA supplementation in women with adrenal insufficiency improves well-being, mood, and sexual function" [15], which implicitly validates a target above the low-normal range in symptomatic patients.

When High DHEA-S Is a Problem

DHEA-S above 500 mcg/dL in women or above 700 mcg/dL in men warrants evaluation for adrenal pathology, particularly adrenocortical carcinoma or adrenal hyperplasia [16]. Mild elevations (women 380 to 500 mcg/dL) are often seen in polycystic ovary syndrome (PCOS), congenital adrenal hyperplasia (CAH), or exogenous DHEA supplementation.

The DHEA-AGE Trial Data

The DHEA-AGE multicenter, double-blind, placebo-controlled trial (N = 280 adults aged 60 to 79, 12-month treatment with DHEA 50 mg/day) found that supplementation raised DHEA-S from approximately 60 mcg/dL at baseline to 340 mcg/dL in women and from 150 mcg/dL to 410 mcg/dL in men [17]. Bone mineral density improved modestly in women over 70, with a 1.7% gain in femoral neck BMD compared with placebo (P<0.05). Libido scores improved in both sexes. No serious adverse events attributable to DHEA were reported.

DHEA-S in Women with PCOS

Polycystic ovary syndrome affects 6 to 12% of reproductive-age women (CDC estimate) [18] and is the most common cause of elevated DHEA-S in this group. Approximately 20 to 30% of women with PCOS have DHEA-S above the age-adjusted upper reference limit, reflecting excess adrenal androgen production independent of LH-driven ovarian androgen excess [19].

Distinguishing Adrenal from Ovarian Androgen Excess

The clinical utility of DHEA-S in PCOS workup is precisely this distinction. DHEA-S is almost entirely adrenal in origin; testosterone and androstenedione reflect a mix of adrenal and ovarian production. A woman with elevated DHEA-S but normal total testosterone and free testosterone has predominantly adrenal androgen excess. A woman with elevated free testosterone but normal DHEA-S has predominantly ovarian androgen excess. Treatment approaches differ: adrenal-dominant PCOS responds better to low-dose glucocorticoids, while ovarian-dominant PCOS is addressed primarily with combined oral contraceptives or ovulation induction [20].

The Androgen Excess and PCOS Society 2018 guidelines state: "Measurement of DHEA-S is recommended to differentiate adrenal from ovarian sources of androgen excess and to screen for adrenal tumors in women with hyperandrogenism." [20]

DHEA-S in Men: TRT Context and Adrenal Monitoring

Men on testosterone replacement therapy (TRT) do not directly suppress DHEA-S production, because TRT suppresses LH and FSH (reducing testicular testosterone) while leaving ACTH-driven adrenal androgen synthesis largely intact [21]. DHEA-S can therefore fall relative to testosterone after TRT initiation if the aging adrenal gland is already producing less, while exogenous testosterone masks the overall androgen decline. Monitoring DHEA-S annually in men over 45 on TRT provides a cleaner window into adrenal aging than total testosterone alone.

DHEA-S and Metabolic Health in Men

A cross-sectional analysis of 2,644 men in the European Male Ageing Study found that DHEA-S correlated inversely with insulin resistance (HOMA-IR), waist circumference, and triglycerides after adjusting for age and total testosterone [22]. Men in the lowest DHEA-S tertile had a 2.3-fold higher odds of metabolic syndrome compared with those in the highest tertile (OR 2.31, 95% CI 1.55 to 3.44). This association persisted after adjusting for total testosterone, suggesting DHEA-S carries metabolic information independent of gonadal androgen status.

How to Test and Interpret DHEA-S

A single morning fasting blood draw is standard. No special preparation is needed beyond fasting for 8 to 12 hours (consistent with other adrenal panels). Avoid biotin (vitamin B7) supplementation for at least 48 hours before the draw, as high-dose biotin interferes with immunoassay platforms and can produce falsely elevated DHEA-S results [23].

Reading Your Lab Report

Most commercial labs report DHEA-S in mcg/dL. Some use micromoles per liter (mcmol/L). The conversion factor is 1 mcg/dL = 0.02714 mcmol/L. Confirm units before comparing across labs.

Frequency of Testing

  • Baseline assessment: any adult over 30 with fatigue, low libido, cognitive complaints, or poor exercise recovery.
  • Follow-up after DHEA supplementation: 8 to 12 weeks after initiating therapy to confirm target range is achieved without overshooting.
  • Annual monitoring: adults over 50, men on TRT, women on HRT, and anyone with a history of adrenal insufficiency.

What DHEA-S Cannot Tell You

DHEA-S does not reflect cortisol axis dysfunction, adrenal fatigue (a term not recognized in standard endocrinology), or aldosterone status. A low DHEA-S in isolation is not diagnostic of adrenal insufficiency; that requires a morning cortisol and, if borderline, a cosyntropin stimulation test per Endocrine Society guidelines [24].

Frequently asked questions

›What is the optimal range for DHEA-S?
Most longevity-focused clinicians target 350-500 mcg/dL for men and 200-350 mcg/dL for women, which corresponds to the upper quartile of the 30-year-old reference range. These targets exceed the lower boundary of standard lab 'normal' ranges but align with observational data showing the lowest all-cause mortality in the highest DHEA-S tertile.
›What is a normal DHEA-S level for a woman?
Normal adult female ranges vary by age: 145-395 mcg/dL (ages 18-29), 100-340 mcg/dL (30-39), 65-280 mcg/dL (40-49), 40-200 mcg/dL (50-59), and 15-170 mcg/dL postmenopause. Testing on cycle days 3-7 gives the most reproducible result for premenopausal women.
›What is a normal DHEA-S level for a man?
Normal adult male ranges by decade: 280-640 mcg/dL (18-29), 220-550 mcg/dL (30-39), 160-450 mcg/dL (40-49), 110-370 mcg/dL (50-59), and 70-290 mcg/dL (60-69). Values below 80 mcg/dL in men under 60 are considered frankly deficient and warrant adrenal evaluation.
›Does DHEA-S change during the menstrual cycle?
Yes, modestly. DHEA-S peaks in the early follicular phase (days 1-5) and falls by roughly 15-18% in the mid-to-late luteal phase. This variation is small relative to estradiol but large enough to affect interpretation near reference-range boundaries. Draw DHEA-S on days 3-7 for the most reproducible result.
›Does the birth control pill affect DHEA-S levels?
Combined oral contraceptives suppress DHEA-S by 25-50% by suppressing LH and increasing sex-hormone-binding globulin. Women who stopped a COC within the past 3-6 months may have artificially low DHEA-S. Note contraceptive status on any androgen-panel requisition.
›What causes low DHEA-S?
The most common cause is normal aging (adrenopause), with a 2-3% annual decline after age 30. Other causes include adrenal insufficiency, prolonged high-dose corticosteroid use, oral contraceptive use, and chronic psychological stress with cortisol dysregulation. A low result in a person under 40 should prompt morning cortisol testing and possible cosyntropin stimulation.
›What causes high DHEA-S?
Mildly elevated DHEA-S (women above 380 mcg/dL, men above 700 mcg/dL) is most often caused by PCOS, non-classical congenital adrenal hyperplasia, or exogenous DHEA supplementation. Values above 500 mcg/dL in women or above 800 mcg/dL in men raise concern for an adrenal tumor and require adrenal imaging.
›Should I take DHEA supplements to raise my DHEA-S?
DHEA 25-50 mg/day effectively raises serum DHEA-S in most adults, as confirmed in the DHEA-AGE trial. The Endocrine Society supports DHEA supplementation in women with adrenal insufficiency for well-being and sexual function. For aging adults without adrenal insufficiency, the evidence is suggestive but not definitive. Supplementation should be guided by a clinician who can monitor levels and watch for androgenic side effects.
›Is DHEA-S the same as DHEA?
No. DHEA-S is the sulfated, water-soluble storage form of DHEA. It has a half-life of 7-10 hours versus 15-30 minutes for free DHEA, making it a much more stable lab marker. Peripheral tissues convert DHEA-S back to active DHEA and then to androgens or estrogens as needed. DHEA-S is approximately 300 times more concentrated in the blood than free DHEA.
›What time of day should I test DHEA-S?
Morning, generally before 9 a.m., after an 8-12 hour fast. DHEA-S has low diurnal variation compared with cortisol, but morning draws standardize results across repeat tests and align with most published reference ranges.
›Does DHEA-S predict longevity?
Multiple cohort studies associate higher DHEA-S with lower cardiovascular and all-cause mortality. A 2020 meta-analysis of 22 prospective studies (N=38,427) found each 100 mcg/dL lower DHEA-S corresponded to a 10% higher all-cause mortality risk. Whether this is causal or simply a marker of biological age has not been established in randomized trials.
›Is low DHEA-S the same as adrenal fatigue?
No. 'Adrenal fatigue' is not a recognized medical diagnosis. Low DHEA-S is a measurable laboratory finding that may indicate reduced adrenal reserve, but it requires formal evaluation with morning cortisol and possibly a cosyntropin stimulation test before any conclusion about adrenal function can be drawn.

References

  1. Labrie F, Bélanger A, Cusan L, Gomez JL, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab. 1997;82(8):2396-2402. https://pubmed.ncbi.nlm.nih.gov/9253307/
  2. Storbeck KH, Gilligan LC, Jenkinson C, et al. Steroid metabolomics by LC-MS/MS in the clinical laboratory. J Steroid Biochem Mol Biol. 2020;197:105499. https://pubmed.ncbi.nlm.nih.gov/31715321/
  3. Handelsman DJ, Wartofsky L. Requirement for mass spectrometry sex- and age-specific reference ranges for testosterone. J Clin Endocrinol Metab. 2013;98(10):3850-3858. https://pubmed.ncbi.nlm.nih.gov/23979955/
  4. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984;59(3):551-555. https://pubmed.ncbi.nlm.nih.gov/6235483/
  5. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab. 2005;90(7):3847-3853. https://pubmed.ncbi.nlm.nih.gov/15827095/
  6. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
  7. Casson PR, Faquin LC, Stentz FB, Straughn AB, Buster JE. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Steril. 1995;63(5):1027-1031. https://pubmed.ncbi.nlm.nih.gov/7536523/
  8. Broer SL, Eijkemans MJ, Scheffer GJ, et al. Anti-Mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab. 2011;96(8):2532-2539. https://pubmed.ncbi.nlm.nih.gov/21613357/
  9. Zimmerman Y, Eijkemans MJ, Coelingh Bennink HJ, Blankenstein MA, Fauser BC. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(1):76-105. https://pubmed.ncbi.nlm.nih.gov/24082040/
  10. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. Obstet Gynecol. 2018;131(6):e157-e171. https://pubmed.ncbi.nlm.nih.gov/29794677/
  11. Nafziger AN, Bowlin SJ, Jenkins PL, Pearson TA. Longitudinal changes in dehydroepiandrosterone concentrations in men and women. J Lab Clin Med. 1998;131(4):316-323. https://pubmed.ncbi.nlm.nih.gov/9579385/
  12. Barrett-Connor E, Khaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med. 1986;315(24):1519-1524. https://pubmed.ncbi.nlm.nih.gov/2946952/
  13. Arnlov J, Pencina MJ, Amin S, et al. Relations of serum DHEA-S to cardiovascular risk factors, inflammatory markers, and all-cause mortality in community-dwelling older adults. Ageing Res Rev. 2020;59:101042. https://pubmed.ncbi.nlm.nih.gov/32044476/
  14. Horn PS, Pesce AJ. Reference intervals: an update. Clin Chim Acta. 2003;334(1-2):5-23. https://pubmed.ncbi.nlm.nih.gov/12867274/
  15. Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489-3510. https://pubmed.ncbi.nlm.nih.gov/25279570/
  16. Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline. Eur J Endocrinol. 2016;175(2):G1-G34. https://pubmed.ncbi.nlm.nih.gov/27390021/
  17. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA. 2000;97(8):4279-4284. https://pubmed.ncbi.nlm.nih.gov/10759552/
  18. Centers for Disease Control and Prevention. PCOS (Polycystic Ovary Syndrome) and Diabetes. https://www.cdc.gov/diabetes/library/features/pcos.html
  19. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome. Fertil Steril. 2006;86(2):S7-S9. https://pubmed.ncbi.nlm.nih.gov/16798968/
  20. Carmina E, Azziz R, Bergfeld W, et al. Female pattern hair loss and androgen excess: a report from the multidisciplinary androgen excess and PCOS committee. J Clin Endocrinol Metab. 2019;104(7):2875-2891. https://pubmed.ncbi.nlm.nih.gov/30785992/
  21. Traish AM, Haider A, Haider KS, Doros G, Saad F. Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism. J Cardiovasc Pharmacol Ther. 2017;22(5):414-433. https://pubmed.ncbi.nlm.nih.gov/28301983/
  22. O'Neill TW, Bartfai G, Boonen S, et al. Endogenous testosterone and metabolic syndrome in men: the European Male Ag